Doma is an innovative biotechnology company with an independent drug research and development pipeline that also functions as a biotech incubator with flexible and diverse operation models.  Our goal is to gather top biotech talent and promising enterpreneurs to establish an extensive presence in the most cutting-edge fields of biotechnology.

  Doma provides incubatees with a range of support, including offices and lab spaces, seed capital investment and pipeline licensing, project management, regulatory registrations, and a comprehensive range of professional clinical stage services.  At early stages, incubatees can leverage the novel antibody-based drugs development platform from Doma's parent company/stakeholder, Biocytogen, and its RenBiologics to develop FIC/BIC fully human antibody drug candidates with clinical and commercial potential, effectively reducing early-stage R&D spending and accelerating clinical development.

Doma’s Operating and Incubation Model:

Operating hatch

Supporting services with high-quality resources

Biomedical technology incubation

Venture capital and pipeline construction from Doma

Spuning out to create exceptional future value and complete IPO